Nankivell PC, Dunn JA, Langman MJ, Mehanna H. Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. Head Neck Oncol. 2012 Jun 25;4(1):40.

Conclusion This feasibility trial has demonstrated the low incidence of OED in the UK and the difficulties in conducting a study because of this. With an incidence of around 1.5/100,000/year and a high proportion of those patients already taking or intolerant of Aspirin, a large multi-centred trial would be required to fulfil the recruitment for this study. The ability of topical non-steroidal anti-inflammatory drugs to modify COX and prostaglandin expression remains an important but unanswered question. Collaboration with centres in other parts of the world with higher incidences of the disease may be required to ensure adequate recruitment.

http://www.oapublishinglondon.com/article/213

Source: Head and Neck Oncology - February 13, 2015 Category: Cancer & Oncology Source Type: research